Translational research of a novel humanized epidermal growth factor receptor-related protein: a putative inhibitor of pan-ErbB Xian-Hua FuJun LiSu-Zhan Zhang Mini Review 23 September 2011 Pages: 1373 - 1376
Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors Patricia LoRussoGeoffrey I. ShapiroEric Masson Original Article 03 April 2011 Pages: 1377 - 1385
t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement Sung-Hsin KuoAnn-Lii ChengLi-Tzong Chen Original Article 05 April 2011 Pages: 1387 - 1395
Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies P. SchöffskiH. DumezG. Giaccone Original Article 05 April 2011 Pages: 1397 - 1403
Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation Giulio MetroR. ChiariL. Crinò Original Article 06 April 2011 Pages: 1405 - 1412
Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer N. FrancesL. ClaretA. Iliadis Original Article 08 April 2011 Pages: 1413 - 1419
Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway Shuang-Jia WangBei SunXue-Wei Bai Original Article 09 April 2011 Pages: 1421 - 1430
Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial David FogelmanMehrdad JafariRobert A. Wolff Original Article 09 April 2011 Pages: 1431 - 1438
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study Ticiana B. LealScot C. RemickDaniel Mulkerin Original Article 09 April 2011 Pages: 1439 - 1447
Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation Cristina P. R. XavierCristovao F. LimaCristina Pereira-Wilson Original Article 11 April 2011 Pages: 1449 - 1457
Resveratrol induces SIRT1- and energy–stress-independent inhibition of tumor cell regrowth after low-dose platinum treatment My BjörklundJeanette RoosMaria Shoshan Original Article 11 April 2011 Pages: 1459 - 1467
Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma Robin E. NorrisJane E. MinturnPeter C. Adamson Original Article 12 April 2011 Pages: 1469 - 1475
Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study Peter Mu-Hsin ChangCheng-Hwai TzengMuh-Hwa Yang Original Article 12 April 2011 Pages: 1477 - 1484
The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib Jiri HorakJeff WhiteChris Twelves Original Article 13 April 2011 Pages: 1485 - 1495
Weekly docetaxel and cisplatin with concomitant radiotherapy in addition to surgery and/or consolidation chemotherapy in stage III non-small cell lung cancer Fatma SenEsra Kaytan SaglamAdnan Aydiner Original Article 17 April 2011 Pages: 1497 - 1505
Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer Apostolia-Maria TsimberidouNancy LewisRazelle Kurzrock Original Article 17 April 2011 Pages: 1507 - 1516
Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor Elena SotoAlexander StaabIñaki F. Trocóniz Original Article 24 April 2011 Pages: 1517 - 1527
Pharmacokinetic evaluation of the vinorelbine–lapatinib combination in the treatment of breast cancer patients Keyvan RezaiS. UrienF. Lokiec Original Article 26 April 2011 Pages: 1529 - 1536
Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells Rebecca G. BagleyLeslie KurtzbergBeverly A. Teicher Original Article 28 April 2011 Pages: 1537 - 1546
Prevention of cisplatin-induced hearing loss by administration of a thiosulfate-containing gel to the middle ear in a guinea pig model Cecilia Engmér BerglinPernilla Videhult PierreGöran Laurell Original Article 02 May 2011 Pages: 1547 - 1556
Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression Ario TakeuchiMasaki ShiotaSeiji Naito Original Article 05 May 2011 Pages: 1557 - 1564
Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors Muhammad Wasif SaifJohn SarantopoulosMurali Beeram Original Article 06 May 2011 Pages: 1565 - 1573
Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials Daniel BinderRalf-Harto HübnerPeter Schlattmann Original Article 06 May 2011 Pages: 1575 - 1583
Preclinical evaluation of the novel multi-targeted agent R1530 Kenneth KolinskyChristian TovarBrian Higgins Original Article 08 May 2011 Pages: 1585 - 1594
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202 Syma IqbalCathryn RankinCharles D. Blanke Original Article 10 May 2011 Pages: 1595 - 1602
Chemotherapy for endometrial carcinoma (GOGO-EM1 study): TEC (paclitaxel, epirubicin, and carboplatin) is an effective remission-induction and adjuvant therapy Tomomi Egawa-TakataYutaka UedaTakayuki Enomoto Original Article 17 May 2011 Pages: 1603 - 1610
Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency Maurice C. van StaverenBarbara Theeuwes-OonkJan Gerard Maring Original Article Open access 18 May 2011 Pages: 1611 - 1617
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors Suzanne LeijenPatricia M. M. B. SoetekouwMark Middleton Clinical Trial Report Open access 28 September 2011 Pages: 1619 - 1628
The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients Jacqueline RamírezKehua WuMark J. Ratain Short Communication 23 August 2011 Pages: 1629 - 1632
Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity Romain GuilhaumouCaroline SolasNicolas Andre Short Communication 04 October 2011 Pages: 1633 - 1638
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function Fabio FarinatiAnna GiacominVeronica Vanin Letter to the Editor 10 November 2011 Pages: 1639 - 1640
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function Jeong Eun KimBaek-Yeol RyooYoon-Koo Kang reply 09 November 2011 Pages: 1641 - 1642